New biosimilar shows promise for treating wet macular degeneration
Disease control
Completed
This study tested a new drug called FYB203, which is a biosimilar (a close copy) of the existing medication Eylea, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial involved 434 participants and compared how well FYB203 worked v…
Phase: PHASE3 • Sponsor: Bioeq GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC